None listed
Conditions
Brief summary
The aim of this study is to work towards developing a diagnostic technique to determine patients response to chemotherapy and surgery using circulating tumour (ct) DNA biomarkers. This will reduce the need for excessive chemotherapy treatment therefore reducing the unwanted adverse effects of treatments. Genes are substances in the body which contain information about characteristics about us as indivuals. Previous studies have found that the majority (more than 9 out of 10) of pancreataic cancers contain a mutation in KRAS gene which can be detected in the blood. Identifying biomarkers are important because: they may be linked with disease progression; they may help to identify people who are most likely to benefit from a certain treatment such as chemotherapy and how much treatment they need; and they help to identify people who have partial or complete response to treatment without the need for chemotherapy after surgery
Interventions
This is a prospective study involving the collection of blood samples for the purposes of measuring circulating tumour DNA from patients with pancreatic adenocarcinoma who are planned to undergo surgical resection
Patients will be treated and followed according to standard protocols.
This is an exploratory, prospective study enrolling patients diagnosed with stage I and II pancreatic adenocarcinoma to investigate the potential use of a novel blood-based biomarker (circulating tumour DNA) as a ma
This is a prospective study involving the collection of blood samples for the purposes of measuring circulating tumour DNA from patients with pancreatic adenocarcinoma who are planned to undergo surgical resection Patients will be treated and followed according to standard protocols. This is an exploratory, prospective study enrolling patients diagnosed with stage I and II pancreatic adenocarcinoma to investigate the potential use of a novel blood-based biomarker (circulating tumour DNA) as a marker of residual disease that predicts later recurrence. Blood collection will occur at two timepoints as follows: Timepoint 1: Baseline - Presurgery Timepoint 2: 4 - 8 Weeks post surgery
Sponsors
Ludwig Institute for Cancer Research
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with resectable pancreatic adenocarcinoma who are to have a resection of their tumour. 2. ECOG performance status 0 - 2. 3. Patients willing to provide written informed consent.
Exclusion criteria
1. History of another primary cancer within the last 5 years, with the exception of non-melanomatous skin cancer and carcinoma in situ of the cervix. 2. Medical or psychiatric condition or occupational responsibilities that may preclude compliance with the protocol. 3. Patients that are not accessible for follow-up. 4. Preoperative chemotherapy or radiotherapy.
Outcome results
None listed